Misplaced Pages

Epsametostat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Boghog (talk | contribs) at 04:29, 6 January 2025 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 04:29, 6 January 2025 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound
Epsametostat
Clinical data
Other namesHH2853
Identifiers
IUPAC name
  • N--6-methyl-1-(6-methylpyridazin-3-yl)-5-ethyl]indolizine-7-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H36F3N7O3
Molar mass611.670 g·mol
3D model (JSmol)
SMILES
  • CC1=NN=C(C=C1)C2=C3C=C(C(=C(N3C=C2)(C)N4CCN(CC4)CC(F)(F)F)C)C(=O)NCC5=C(C=C(NC5=O)C)OC
InChI
  • InChI=InChI=1S/C31H36F3N7O3/c1-18-6-7-25(38-37-18)22-8-9-41-26(22)15-23(29(42)35-16-24-27(44-5)14-19(2)36-30(24)43)20(3)28(41)21(4)40-12-10-39(11-13-40)17-31(32,33)34/h6-9,14-15,21H,10-13,16-17H2,1-5H3,(H,35,42)(H,36,43)/t21-/m1/s1
  • Key:BIABSPVTTUDBEO-OAQYLSRUSA-N

Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.

References

  1. An R, Li YQ, Lin YL, Xu F, Li MM, Liu Z (February 2023). "EZH1/2 as targets for cancer therapy". Cancer Gene Therapy. 30 (2): 221–235. doi:10.1038/s41417-022-00555-1. PMID 36369341.
  2. Wei L, Mei D, Hu S, Du S (August 2024). "Dual-target EZH2 inhibitor: latest advances in medicinal chemistry". Future Medicinal Chemistry. 16 (15): 1561–1582. doi:10.1080/17568919.2024.2380243. PMID 39082677.
  3. "Epsametostat". PatSnap.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: